Treatment of high-risk neuroblastoma.

Korean journal of pediatrics
Ki Woong Sung

Abstract

Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trials, including tandem HDCT/autoSCT, high-dose (131)I-metaiodobenzylguanidine treatment, and immunotherapy with NB specific antibody, have been undertaken and pilot studies have reported encouraging results. Nonetheless, about half of high-risk NB patients still experience treatment failure and have no realistic chance for cure with conventional treatment options alone after relapse. Therefore, a new modality of treatment is warranted for these patients. In recent years, several groups of investigators have examined the feasibility and effectiveness of reduced-intensity allogeneic stem cell transplantation (RI alloSCT) for the treatment of relapsed/progressed NB. Although a graft-versus-tumor effect has not yet been convincingly demonstrated in the setting of relapsed NB, the strategy of employing RI alloSCT has provided hope that treatment-related mortality will be reduced and a therapeutic benefit will emerge. However, alloSCT for NB ...Continue Reading

References

Apr 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T LookG M Brodeur
Oct 31, 1985·The New England Journal of Medicine·R C SeegerD Hammond
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K K MatthayN K Ramsay
Jan 2, 1997·Bone Marrow Transplantation·M de LimaR E Champlin
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K K MatthayD Price
Mar 28, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T PhilipF Chauvin
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D FrappazJ M Zucker
Jun 28, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J P RadichF R Appelbaum
May 18, 2001·Nature·F R Appelbaum
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory A YanikRaymond J Hutchinson
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Morris KletzelSusan L Cohn
Apr 15, 2003·Journal of Korean Medical Science·Kyung Ha RyuTai Ju Hwang
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rani E GeorgeLisa Diller
Jul 25, 2006·Transplantation·Masahiro HirayamaAtsuko Nakagawa
Apr 24, 2007·Bone Marrow Transplantation·A MarabelleJ Kanold
Jul 16, 2008·Pediatric Blood & Cancer·Wendy L HobbieJill P Ginsberg
Aug 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jacek ToporskiAlbert N Békássy
Oct 1, 2010·The New England Journal of Medicine·Alice L YuUNKNOWN Children's Oncology Group

❮ Previous
Next ❯

Citations

May 16, 2019·Open Biology·Ricky M TriggSuzanne D Turner
Mar 31, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ian R MarshBryan P Bednarz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.